News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Promising Results for Sacituzumab Govitecan in Cisplatin-Ineligible Metastatic Urothelial Cancer
Photo of Daniel P. Petrylak from medicine.yale.edu
Sep 15, 2024, 16:36

Promising Results for Sacituzumab Govitecan in Cisplatin-Ineligible Metastatic Urothelial Cancer

Eda Eylemer Mocan, Medical oncologist at Ankara university, shared a recent article by Daniel P. Petrylak on X:

“TROPHY-U-01 Cohort 2
SG in Metastatic Urothelial Cancer

  • Cisplatin-Ineligible
  • Progressing after ICI
  • Med f/u 9.3 m, ORR 32%, DOR 5.6 m
  • Grade ≥3 AE 87% of pts
  • Neutropenia 34%
  • Anemia 24%
  • Fatigue 18%
  • Diarrhea 16%

TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.

Authors: Daniel P. Petrylak, MD, Scott T. Tagawa, MD, Rohit K. Jain, MD, Manojkumar Bupathi, MD, Arjun Balar, MD,Arash Rezazadeh Kalebasty, MD, Saby George, MD and Petros Grivas, MD, PhD

Promising Results for Sacituzumab Govitecan in Cisplatin-Ineligible Metastatic Urothelial Cancer

Source: Eda Eylmer Mocan/X

anemia cancer diarrhea Eda Eylemer Mocan neutropenia OncoDaily Oncology Sacituzumab govitecan
Special Coverage
Career
Dec 21, 2024, 07:45
OncoInfluencers to Follow on Social Media: Dr. Liang Cheng
Insight
Dec 21, 2024, 07:31
Update on U.S. regulatory review of subcutaneous amivantamab for EGFR + lung cancer
Science
Dec 21, 2024, 07:05
Naseema Gangat: Practical prognostic tool for the current standard of care in older/unfit AML
Blog
Dec 21, 2024, 05:54
LCC in Spanish: LALCA 2024 Highlights
Blog
Dec 21, 2024, 05:50
The Opportunities Are Endless: CU Cancer Center leader Enrique Soto Pérez de Celis signs key international agreement
Insight
Dec 21, 2024, 05:42
Raffaella Casolino: How to integrate cancer into crisis?
Insight
Dec 21, 2024, 05:01
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
Blog
Dec 21, 2024, 05:01
Omolola Salako: A year ago, Pearl Oncology Specialist Hospital became a 24-hour, 10-bed cancer center
Science
Dec 21, 2024, 04:57
Alexandre Chan: Updates on repurposing riluzole as a treatment for cancer-related cognitive impairment
Blog
Dec 21, 2024, 04:55
Milan Mishkovikj: The Patient at the Center - Value-Based Healthcare in Oncology
Insight
Dec 21, 2024, 04:52
Do national cancer control plans address care and research for children and AYAs - SIOP
Insight
Dec 21, 2024, 04:36
A holistic global strategy for incorporating cancer care into crisis response initiatives - The Institute of Cancer and Crisis